TransMedics Group, Inc.

TransMedics Group, Inc. (TMDX) priced its initial public offering on May 2, 2019 at $16.00 per share, within its $15.00–$17.00 range, raising $91M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $323.8M. Ropes & Gray advised the company and Davis Polk advised the underwriters.

TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy for patients with end-stage organ failure. Its Organ Care System keeps organs in a living, functioning state outside the body, replacing static preservation, to allow organ assessment and optimization.

Status

IPO

Ticker

TMDX

Exchange

Nasdaq Global Market

Priced

May 2, 2019

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$91M

Market cap at IPO price

$323.8M

First filed

Apr 5, 2019

Company counsel

Ropes & Gray

Underwriters' counsel

Davis Polk

Sector

Healthcare

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.